Compounded Semaglutide: What It Is, Is It Safe, and Is It Legal?

What Is Compounded Semaglutide?

Pharmaceutical compounding is the practice of preparing a medication tailored to a patient's specific needs — traditionally used for patients with allergies to inactive ingredients, dose requirements unavailable in commercial forms, or difficulty swallowing standard formulations.

Compounded semaglutide emerged as a parallel market to Ozempic and Wegovy during the semaglutide shortage of 2022–2024. As demand for GLP-1 medications far outpaced supply, compounding pharmacies began manufacturing semaglutide independently, sourcing the active pharmaceutical ingredient (API) from chemical suppliers rather than Novo Nordisk. These preparations were sold primarily through telehealth platforms at a fraction of branded costs.

At peak, hundreds of telehealth companies were prescribing and dispensing compounded semaglutide to hundreds of thousands of patients.

Legal Status: What Changed in 2024–2025

The FDA permits compounding of drugs that are on its drug shortage list. During the Ozempic/Wegovy shortage, compounded semaglutide was technically legal under shortage provisions.

In late 2024, the FDA declared the semaglutide shortage resolved. This removed the legal basis for most compounding of semaglutide — compounders could no longer rely on the shortage exemption. The FDA issued letters to compounders requiring them to stop producing semaglutide and set compliance deadlines.

The result as of 2025–2026:

• 503A compounding pharmacies (patient-specific, single-unit) generally cannot legally compound semaglutide for most patients
• 503B outsourcing facilities have stricter regulations and most stopped compounding semaglutide
• Some compounders continue operating in legal gray areas, claiming exemptions or using modified formulations (semaglutide salts, different esters)
• Enforcement is inconsistent and ongoing

The legal situation is still evolving. Patients interested in compounded semaglutide should verify current regulatory status at time of inquiry, as this is an area of active FDA enforcement.

How Compounded Semaglutide Differs From Ozempic/Wegovy

The Safety Questions

The safety concerns around compounded semaglutide are real and important:

Purity and potency variability. Compounding pharmacies source API from various suppliers, and quality control standards vary significantly. The FDA has found compounded semaglutide products with underdosing, overdosing, and contamination in inspection reports. Without the FDA approval process, there is no standardized validation of what is actually in the vial.

Formulation differences. Some compounders use semaglutide sodium or semaglutide acetate — salt forms not present in Novo Nordisk's products. Whether these have equivalent pharmacokinetics, safety, and efficacy as the approved formulation is not established by clinical data.

Dosing errors. Branded Ozempic and Wegovy use auto-injector pens with pre-set doses that are difficult to miscalculate. Most compounded semaglutide is dispensed as a vial requiring the patient to draw up and inject the dose themselves. Dosing errors — both under- and overdosing — are significantly more likely with patient-drawn vials.

No post-market safety reporting. Adverse events from compounded medications are not captured in the FDA's pharmacovigilance system the way branded drug adverse events are.

The FDA has issued specific warnings about compounded semaglutide products containing incorrect dosing instructions and undisclosed additives.

Who Might Still Consider Compounded Semaglutide

Despite the regulatory landscape, some patients continue to pursue compounded semaglutide:

• Uninsured patients who cannot afford branded options and don't qualify for patient assistance programs
• Patients who have had good experience with specific compounders with demonstrable quality controls (third-party testing)
• Patients in states where compounders are operating legally under different interpretations of FDA guidance

If pursuing compounded semaglutide:

• Use a 503B outsourcing facility (higher standards than 503A pharmacies)
• Ask for certificates of analysis (third-party purity testing)
• Work with a licensed prescriber who will monitor your response
• Understand the legal and safety tradeoffs explicitly

Tirzepatide Self-Pay Vials: The Better Alternative?

For uninsured or cash-pay patients who were attracted to compounded semaglutide primarily for cost reasons, Eli Lilly's official self-pay tirzepatide vials (sold through LillyDirect.com at $399–549/month) represent a superior option:

• FDA-approved medication (not compounded)
• Validated purity and dosing
• Comparable or superior efficacy to semaglutide
• Lower cost than either branded semaglutide or many compounders
• Requires drawing the dose from a vial (same as compounded), but from a validated source

Bottom Line

Compounded semaglutide emerged from a genuine market need — the branded shortage made Ozempic and Wegovy inaccessible for many patients. The shortage resolution has significantly changed its legal status and narrowed access. The safety concerns — variable purity, dosing errors, unvalidated formulations — are real. For cost-driven patients, tirzepatide's official self-pay vials offer a vetted alternative. For patients who continue to explore compounded options, rigorous compounder vetting (503B, third-party testing, licensed prescriber oversight) is essential.

Sources

• FDA, "FDA alerts patients and health care professionals about risks of compounded GLP-1 drugs," FDA.gov, 2024
• Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM, 2021
• FDA, "Compounding and the FDA: Questions and Answers," FDA.gov
• Novo Nordisk, Wegovy Prescribing Information, 2024